Browse/search for people

Publication - Dr Andrew Davidson

    BASP1 interacts with estrogen receptor α and modifies the tamoxifen response

    Citation

    Marsh, L, Carrera, S, Shandilya, J, Heesom, K, Davidson, A, Medler, KF & Roberts, S, 2017, ‘BASP1 interacts with estrogen receptor α and modifies the tamoxifen response’. Cell Death and Disease, vol 8.

    Abstract

    Tamoxifen binds to estrogen receptor α (ERα) to elicit distinct responses that vary by cell/tissue type and status, but the factors that determine these differential effects are unknown. Here we report that the transcriptional corepressor BASP1 interacts with ERα and in breast cancer cells, this interaction is enhanced by tamoxifen. We find that BASP1 acts as a major selectivity factor in the transcriptional response of breast cancer cells to tamoxifen. 40% of the genes that are regulated by tamoxifen in breast cancer cells are BASP1-dependent, including several genes that are associated with tamoxifen resistance. BASP1 elicits tumour-suppressor activity in breast cancer cells and enhances the anti-tumourigenic effects of tamoxifen treatment. Moreover, BASP1 is expressed in breast cancer tissue and is associated with increased patient survival. Our data has identified BASP1 as an ERα cofactor that plays a central role in the transcriptional and anti-tumourigenic effects of tamoxifen.

    Full details in the University publications repository